PlainPharmaWatch

CMS Open Payments · Tool

Viseon, Inc. vs Endo USA, Inc.

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

Viseon, Inc. has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 5,966, versus 351 for the other company. Its single largest recorded recipient represents 76.8% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

Viseon, Inc.
HHI 5,966 · top recipient 76.8%
Ranked #266 of 1,838 companies by HHI
Endo USA, Inc.
HHI 351 · top recipient 12.0%
Ranked #1,418 of 1,838 companies by HHI

Payment Overview

Company A

Viseon, Inc.

Total Payments
$3.2M
% of Industry
0.0%
Transactions
86
Avg per Transaction
$37.5K
Recipients
67
Avg per Recipient
$48.2K
Payment Types
3
Top Payment Type
Consulting Fee
Company B

Endo USA, Inc.

Total Payments
$3.2M
% of Industry
0.0%
Transactions
10,792
Avg per Transaction
$300.52
Recipients
10,750
Avg per Recipient
$301.69
Payment Types
7
Top Payment Type
Compensation for Services Other Than Consulting

Highlighted values indicate the higher figure for each metric.

Total payments compared

Viseon, Inc. vs Endo USA, Inc. - total reported payments in CMS Open Payments PY2024

Endo USA, Inc.$3.2MViseon, Inc.$3.2M

General Payment Types Breakdown

Category shares use each company's General Payments total, not the all-tracks (General + Research + Ownership) hero figure.

Viseon, Inc.

Consulting Fee $118.3K

80.9%

Debt Forgiveness $23.6K

16.2%

Food and Beverage $4.3K

3.0%

Endo USA, Inc.

Compensation for Services Other Than Consulting $421.6K

28.0%

Grant $383.8K

25.5%

Consulting Fee $321.8K

21.4%

Food and Beverage $286.8K

19.0%

Travel and Lodging $77.7K

5.2%

Space Rental or Facility Fees $15.4K

1.0%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

Viseon, Inc.

  1. 1

    Rajiv K Sethi

    $112,367.02 · 16 txns

  2. 2

    Virginia Mason Medical Center

    $7,005.76 · 5 txns

  3. 3

    Ucsd Medical Center

    $5,886.52 · 1 txns

  4. 4

    Uci Medical Center

    $3,622.07 · 1 txns

  5. 5

    Orlando Health

    $3,462.29 · 1 txns

Endo USA, Inc.

  1. 1

    UNIVERSITY OF MIAMI HOSPITAL

    $181,200.00 · 1 txns

  2. 2

    JEFFREY FREID

    $128,675.00 · 17 txns

  3. 3

    DAMON ADAMANY

    $81,582.66 · 74 txns

  4. 4

    UNIVERSITY OF WASHINGTON MED CTR

    $62,500.00 · 3 txns

  5. 5

    PROSPER BENHAIM

    $60,203.74 · 21 txns

Summary Comparison

Metric Viseon, Inc. Endo USA, Inc.
Total Payments $3.2M $3.2M
% of Industry Total 0.0% 0.0%
Transaction Count 86 10,792
Avg per Transaction $37.5K $300.52
Recipient Count 67 10,750
Avg per Recipient $48.2K $301.69
Payment Type Count 3 7
Top Payment Type Consulting Fee Compensation for Services Other Than Consulting

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.